LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Search

REVOLUTION Medicines Inc

Închisă

SectorSănătate

41.83 3.36

Rezumat

Modificarea prețului

24h

Curent

Minim

40.78

Maxim

42.55

Indicatori cheie

By Trading Economics

Venit

-38M

-195M

EPS

-1.12

Angajați

534

EBITDA

-37M

-213M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+73.63% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-35M

7.6B

Deschiderea anterioară

38.47

Închiderea anterioară

41.83

Sentimentul știrilor

By Acuity

34%

66%

104 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2025, 22:34 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mai 2025, 22:43 UTC

Câștiguri

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business to AGL

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mai 2025, 22:05 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mai 2025, 22:04 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 21:15 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Rev $2.65B >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Net $115M >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q EPS $5.44 >CSU.T

12 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

12 mai 2025, 20:44 UTC

Top știri

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mai 2025, 20:31 UTC

Top știri

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mai 2025, 20:24 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mai 2025, 20:22 UTC

Achiziții, Fuziuni, Preluări

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mai 2025, 20:15 UTC

Câștiguri

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mai 2025, 20:10 UTC

Câștiguri

Blink Charging 1Q Rev $20.8M >BLNK

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

73.63% sus

Prognoză pe 12 luni

Medie 70.18 USD  73.63%

Maxim 80 USD

Minim 57 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

12

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

104 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.